Rigel Pharmaceuticals Reports Initial Efficacy, Safety Data from Cancer Drug Study

MT Newswires Live12-10

Rigel Pharmaceuticals (RIGL) said Monday R289 showed "promising" initial efficacy and safety data in its ongoing phase 1b study evaluating safety and tolerability in patients with relapsed or refractory lower-risk myelodysplastic syndrome.

The drug candidate has demonstrated evidence of transfusion independence in elderly patients, Chief Medical Officer Lisa Rojkjaer said.

The company said R289 was "generally well-tolerated," with the most common treatment emergent adverse events being diarrhea and fatigue, and chills, nausea and pruritus, which were all grade 1/2.

One patient discontinued the study due to drug-related adverse events and another discontinued the trial due to adverse effects not related to the drug, the company said.

Rigel shares were down nearly 5% in recent trading.

Price: 24.24, Change: -1.22, Percent Change: -4.77

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment